REGULATORY DIGEST // BREMELANOTIDE // NDA 210557 - 2019
PT-141 is approved for one narrow use — and sold, separately, as something with no oversight at all.
A status-and-access reading of the bremelanotide record: the single FDA-approved indication, the off-label edges, the research-chemical form, and the remote-care context — each figure attributed, no dose recommended.
Before the details
Here is PT-141 in plain words. It is a lab-made copy of a natural brain signal called alpha-MSH, and it switches on certain receptors (docking points on cells) in the brain that help drive sexual desire. One version of it — under the generic name bremelanotide — is an FDA-approved prescription medicine, but only for one specific group: premenopausal women whose low sexual desire causes them real distress (a condition doctors call HSDD). That is the entire approved use. Using it in men, in postmenopausal women, for erections, for "performance," or for weight is off-label — meaning studied but not approved — or purely experimental. Separately, a powder labeled "PT-141" is sold as a research chemical with no check on what is actually in the vial. This page summarizes what the studies and the drug label actually report — including the downsides, which are on PT-141 effects — and it recommends no dose to anyone.
What is PT-141
PT-141 is the development name for bremelanotide, a synthetic cyclic heptapeptide — a ring of seven amino acids — that mimics alpha-MSH (alpha-melanocyte-stimulating hormone), a natural messenger your body makes from a precursor protein called POMC [1]. It activates melanocortin receptors, mainly MC4R and MC3R (two of a five-member receptor family), which sit in the brain rather than in blood vessels [1]. That central location is the whole point: in rats, nonhuman primates, and men with erectile dysfunction, systemic PT-141 produced dose-dependent erectile activity and switched on hypothalamic neurons, a pattern that points to the brain, not blood flow, as the site of action [1]. The approval, however, rests on a different endpoint entirely — sexual desire in women [3].
What is PT-141 peptide
The PT-141 peptide is chemically distinct from the linear melanocortins it descends from. Its cyclic lactam structure — a closed ring formed by a bridge between two amino-acid side chains — makes it more stable than straight-chain peptides [1]. Structurally it is a close relative of another melanocortin agonist, melanotan II, but with the tail amide swapped for a carboxylic acid. None of that chemistry changes the regulatory picture: only the pharmaceutical product, dispensed by prescription under the generic name bremelanotide, carries an approval. Material sold under the bare label "PT-141 peptide" as a research chemical sits outside that framework, with no regulatory oversight of identity, purity, or concentration.
The one approved use, stated precisely
Bremelanotide was approved by the FDA on June 21, 2019 (NDA 210557) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women [7]. "Acquired" means the low desire developed after a period of normal desire; "generalized" means it is not tied to a specific partner or situation. Two identical Phase 3 trials (RECONNECT, 1,267 women combined) met both coprimary endpoints: a +0.35 improvement in the desire-domain score and a -0.33 reduction in desire-related distress versus placebo over 24 weeks (P<.001 for each) [3]. The drug is not approved for men, for postmenopausal women, for erectile dysfunction, or to enhance performance [9]. Everything outside that one indication is off-label or experimental, and this digest labels it that way throughout.
Access and remote-care context
Because PT-141's lead use is a sensitive sexual-health condition, the access question matters, and the literature has begun to address it. A 2020 review examined how telemedicine is used for sexual-medicine patients, describing remote-evaluation workflows and the access considerations that come with prescribing sexual-health therapies [8]. A 2025 cross-country study documented how widely telemedicine was adopted for sexual medicine across eight countries during the pandemic [15]. This site does not connect anyone to a prescriber and dispenses nothing; it summarizes that published context so a reader understands the difference between the regulated, prescribed product and the unregulated research-chemical form. For the reported upsides and downsides, see PT-141 benefits and the full PT-141 effects page.